Study guide

3.1 Prescription Drug Benefit Design & PBM Operations

Certified Employee Benefit Specialist CEBS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: CEBS Framework & The Benefits Environment

1.1 CEBS Program Structure & Credentialing Tracks 1.2 The Employee Benefits Environment & Total Rewards Strategy 1.3 Risk Management & Financing Principles in Group Benefits

2 Chapter 2: GBA 1 — Managed Health Care & Account Mechanics

2.1 Managed Health Care Models & Plan Design 2.2 Consumer-Directed Health Plans & Account Mechanics 2.3 Section 125 Cafeteria Plans & Flexible Benefit Design

3 Chapter 3: GBA 1 — Prescription Drugs, Specialty Benefits & Wellness

3.1 Prescription Drug Benefit Design & PBM Operations 3.2 Dental, Vision, and Hearing Care Programs 3.3 Behavioral Health, EAPs & Workplace Wellness Compliance 3.4 Workplace Wellness Program Design, Incentives & Outcome Measurement 3.5 Integrated Case Study: Diagnosing & Remedying Prescription Drug Cost Increases

4 Chapter 4: GBA 1 — Health Plan Regulation & Statutory Mandates

4.1 ACA Employer Mandate & Market Reforms 4.2 COBRA Continuation Coverage Requirements & Administration 4.3 HIPAA Portability, Privacy, and Security for Group Health Plans 4.4 The No Surprises Act & Transparency in Coverage

5 Chapter 5: GBA 2 — Health Care System Dynamics & Network Design

5.1 U.S. Health Care System Dynamics & Value-Based Payment Models 5.2 Provider Network Architecture, Contracting & Reimbursement 5.3 Health Care Quality Measurement & Utilization Management 5.4 Controlling Risk Factors & Integrated Patient Care 5.5 Participant Response to Health Plan Pricing

6 Chapter 6: GBA 2 — Underwriting, Rating & Funding Strategies

6.1 Group Health Underwriting, Pricing & Rating Methodologies 6.2 Self-Funding Mechanics, Administration & Level-Funded Plans 6.3 Stop-Loss Insurance Design & Risk Transfer 6.4 Claims Lag, Reserving & Financial Underwriting Analysis 6.5 The Small-Group and Individual Insurance Market

7 Chapter 7: GBA 2 — Disability, Life & Long-Term Care Programs

7.1 Group Short-Term and Long-Term Disability Plans 7.2 Group Term Life and AD&D Insurance 7.3 Long-Term Care Insurance & Worksite Voluntary Benefits 7.4 Integrated Case Study: Employee Benefits — Balancing Competing Constraints

8 Chapter 8: GBA/RPA 3 — ERISA Statutory Framework & Plan Governance

8.1 ERISA Title I Statutory Framework & Preemption Doctrine 8.2 Plan Documentation, SPDs, SMMs & Form 5500 Reporting 8.3 Fiduciary Standards, Duties & Prohibited Transactions 8.4 ERISA in Practice: Claims Procedures, Appeals & Enforcement

9 Chapter 9: GBA/RPA 3 — Audits, Vendor Oversight & Cybersecurity

9.1 Benefit Audits, Compliance Reviews & Correction Programs 9.2 Vendor Management, RFPs, SLAs & Benefits Analytics 9.3 Cybersecurity Governance & Data Privacy for Benefit Plans 9.4 The Benefits Industry: Carriers, TPAs, Brokers & Consultants 9.5 Integrated Case Study: Preparing for & Surviving a Benefits Plan Data Breach

10 Chapter 10: GBA/RPA 3 — Social Insurance, Retiree Benefits & Global Strategy

10.1 Social Security, Medicare & Employer Plan Coordination 10.2 Retiree Health Benefit Strategies & OPEB Accounting 10.3 Global Employee Benefits & Strategic Innovation 10.4 Financial Product Innovation & Retirement Vendor Management

11 Chapter 11: RPA 1 — Qualified Plan Fundamentals & DB Pensions

11.1 Qualified Plan Foundations & Nondiscrimination Testing 11.2 Defined Benefit Pension Plan Design & Actuarial Concepts 11.3 PBGC Insurance Coverage & Plan Terminations

12 Chapter 12: RPA 1 — Defined Contribution Structures & 401(k) Plans

12.1 Core Defined Contribution Plans: Profit-Sharing & ESOPs 12.2 401(k) Plans: Elective Deferrals, Testing & Safe Harbors 12.3 Section 403(b) and 457 Deferred Compensation Plans 12.4 SECURE Act & SECURE 2.0 Modernizations 12.5 Defined Contribution Practice Issues: Forfeitures, Missing Participants, ESG & Crypto

13 Chapter 13: RPA 1 — Small Business Plans, IRAs & Executive Compensation

13.1 Small Employer Retirement Solutions: SEPs, SIMPLEs & PEPs 13.2 Individual Retirement Arrangements (IRAs) & Rollover Rules 13.3 Executive Nonqualified Deferred Compensation & IRC §409A 13.4 Stock Compensation Plans: Options, Restricted Stock, RSUs & ESPPs 13.5 Integrated Case Study: Retirement Planning — Participant Goals & Strategic Results

14 Chapter 14: RPA 2 — Capital Markets, Portfolio Theory & Asset Allocation

14.1 Capital Markets, Risk-Return Metrics & Modern Portfolio Theory 14.2 Asset Allocation Strategies, Target-Date Funds & QDIAs 14.3 Investment Vehicles: CITs, Mutual Funds & Lifetime Income 14.4 Active vs. Passive Strategies, Investment Managers & Plan Intermediaries

15 Chapter 15: RPA 2 — Behavioral Finance, Plan Operations & Investment Governance

15.1 Behavioral Finance, Choice Architecture & Financial Wellness 15.2 Hybrid Plans, Participant Loans, Hardships & RMDs 15.3 Fiduciary Investment Governance, IPS & Fee Disclosures 15.4 Plan Sponsor Administrative Responsibilities & Participant Services 15.5 Integrated Case Study: Assessing Fiduciary Concerns Under Threat of Litigation

3.1 Prescription Drug Benefit Design & PBM Operations

Key Takeaways Explain This Topic AI

Prescription drug benefit architecture relies on Pharmacy Benefit Managers (PBMs) to administer pharmacy networks, adjudicate real-time point-of-sale claims, establish formularies, and negotiate manufacturer rebates.

Formulary designs have shifted from traditional open or closed lists to multi-tiered incentive formularies (Tier 1 generic through Tier 4/5 specialty/biologics) to steer members toward clinically effective, lower-cost therapies.

PBM financial contracting models fundamentally differ between traditional 'spread pricing' (where the PBM retains the margin between sponsor billing and pharmacy reimbursement) and transparent 'pass-through' pricing (charging actual pharmacy acquisition costs plus a disclosed administrative fee).

Clinical utilization management tools—such as Prior Authorization (PA), Step Therapy (fail-first protocols), Quantity Limits (QL), and mandatory generic substitution with DAW penalties—are critical levers for controlling drug trend.

Specialty pharmaceuticals and biologics represent the largest cost-growth sector in group health benefits, necessitating specialized management via biosimilar adoption, site-of-care optimization, and copay accumulator or maximizer programs.

Last updated: September 2026

Architecture of Prescription Drug Benefits

Prescription drug benefits represent one of the most visible, high-frequency, and rapidly escalating components of modern employer-sponsored health programs. Historically, prescription drugs were reimbursed under major medical policies as basic indemnity expenses, requiring employees to pay out of pocket, collect paper receipts, and submit manual claims subject to the major medical deductible and coinsurance. Today, prescription drug coverage is almost universally delivered through a specialized, managed prescription drug program administered by a Pharmacy Benefit Manager (PBM) .

Plan sponsors generally structure prescription drug benefits under one of two operational configurations:

Carve-In Arrangements : The prescription drug benefit is bundled directly within the major medical plan contract through a commercial health insurance carrier or third-party administrator (TPA). While the medical carrier may subcontract underlying pharmacy administration to an affiliated or captive PBM (e.g., Evernorth/Cigna, Caremark/CVS Health, OptumRx/UnitedHealth), the plan sponsor maintains a single contract, integrated deductible, and combined customer service interface.

Carve-Out Arrangements : The plan sponsor contracts directly with an independent PBM to manage pharmacy benefits separately from the medical plan. Carve-out arrangements allow self-funded employers to negotiate customized formulary designs, direct manufacturer rebate pass-through terms, tailored clinical utilization programs, and independent audit rights.

At the core of PBM operations is real-time electronic point-of-sale (POS) claims adjudication . When a plan participant presents a prescription at a participating retail pharmacy, the pharmacy management system transmits encrypted transaction data using National Council for Prescription Drug Programs (NCPDP) standards to the PBM's adjudication engine. Within milliseconds, the PBM verifies member eligibility, checks formulary status, calculates patient cost-sharing (copayment or coinsurance), performs automated Drug Utilization Review (DUR) for contraindications and drug-drug interactions, and transmits the approved reimbursement amount back to the dispensing pharmacist.

Formulary Design & Incentive Tier Structures

A formulary is an evidence-based, continually updated compendium of prescription medications approved for coverage under the health plan. Formularies are developed and maintained by a Pharmacy & Therapeutics (P&T) Committee , comprised of independent practicing physicians, clinical pharmacists, and pharmacoeconomic experts. The P&T committee evaluates peer-reviewed clinical trial data, FDA labeling, therapeutic efficacy, safety profiles, and clinical guidelines before considering financial net-cost factors.

Types of Formulary Architecture

Open Formulary : The plan provides coverage for virtually all FDA-approved prescription drugs, with minimal exclusions. While member choice is maximized, cost containment is extremely weak because the plan lacks leverage to negotiate manufacturer rebates or redirect utilization to lower-cost therapeutic equivalents.

Closed Formulary : The plan exclusively covers medications listed on the formulary. Non-formulary medications receive zero plan reimbursement, requiring the member to pay 100% of the retail cost unless an exception is granted through a formal medical necessity appeal.

Incentive / Tiered Formulary : The dominant model in employer benefit design. Rather than excluding non-preferred medications outright, the plan establishes variable cost-sharing tiers that financially motivate participants and prescribers to choose clinically effective, lower-cost medications.

Formulary Tier Typical Medication Class Clinical & Financial Objective Typical Member Cost-Share

Tier 1: Generic Drugs Chemically identical bioequivalent copies of off-patent brand drugs Lowest net cost; high clinical interchangeability; primary driver of generic dispensing rate (GDR) Low copayment ($5–$15)

Tier 2: Preferred Brand Brand-name drugs without generic equivalents that offer favorable clinical efficacy and high manufacturer rebates Preferred brand selection within a therapeutic class Moderate copayment ($30–$60)

Tier 3: Non-Preferred Brand Brand drugs with available generic alternatives or non-rebated branded competitors Discourages use when lower-cost therapeutic equivalents exist Higher copayment or coinsurance ($75–$125 / 30%–50%)

Tier 4 / Tier 5: Specialty & Biologics High-cost biologics, injectable therapies, oral oncology, and complex chronic disease medications Requires specialized handling, clinical monitoring; manages extreme unit cost exposure Coinsurance (20%–40%) often subject to a maximum dollar cap (e.g., $150–$300/script)

PBM Revenue Models & Contracting Dynamics

Plan sponsors evaluating PBM contracts must navigate complex financial arrangements that govern how PBMs generate revenue. The two primary financial contracting models are spread pricing and pass-through (transparent) pricing .

Spread Pricing vs. Pass-Through Transparent Pricing

Spread Pricing (Traditional Model) : The PBM contracts separately with the plan sponsor and network pharmacies. The PBM bills the plan sponsor an agreed-upon contracted rate (e.g., Average Wholesale Price [AWP] minus 18% plus a $2.00 dispensing fee) but reimburses the dispensing pharmacy a lower amount (e.g., AWP minus 22% plus a $1.00 dispensing fee). The PBM retains the difference—the spread —as profit. Under spread pricing, the plan sponsor has price predictability on paper but lacks visibility into the true acquisition cost of medications, particularly for generic drugs governed by proprietary Maximum Allowable Cost (MAC) lists.

Pass-Through / Transparent Pricing : The PBM charges the plan sponsor the exact reimbursement amount paid to the network dispensing pharmacy, with zero markup or spread. In exchange, the plan sponsor pays a transparent, explicit administrative fee (e.g., $1.50–$3.50 per adjudicated claim). Pass-through contracts typically mandate 100% pass-through of all manufacturer rebates, discounts, and manufacturer administrative fees, supported by comprehensive audit rights.

  • Dimension Spread Pricing Model Pass-Through (Transparent) Model
  • Billing Basis Predetermined discount off AWP billed to sponsor Actual amount paid to dispensing pharmacy

PBM Margin Source Arbitrage spread between billed rate and paid rate Fixed, disclosed per-claim administrative fee

Generic Pricing (MAC) Proprietary, undisclosed MAC lists generating PBM profit True network MAC rate passed directly to plan

Rebate Treatment PBM often retains a percentage of manufacturer rebates 100% of rebates credited directly to plan sponsor

Auditability Difficult; transaction-level pharmacy remittance hidden Fully auditable down to pharmacy claim payment level

Manufacturer Rebates & Revenue Streams

Pharmaceutical manufacturers pay substantial rebates to PBMs in exchange for favorable formulary placement (e.g., Tier 2 preferred status over a competitor's product) or exclusive formulary positioning. Rebates fall into three broad categories:

Formulary Access Rebates : Fixed percentage discounts paid on all dispensed units of a drug for securing inclusion on the formulary.

Market-Share / Volume Rebates : Tiered rebates that increase as the drug achieves specific market-share thresholds within its therapeutic class against competing drugs.

Price Protection Rebates : Penalties paid by the manufacturer to the PBM/plan sponsor if the manufacturer increases the wholesale acquisition cost (WAC) of the drug faster than a contractually defined benchmark (e.g., Consumer Price Index [CPI-U]).

In addition to rebates, PBMs may collect manufacturer administrative fees (typically 3%–5% of WAC), data-sharing fees, and clinical program management fees. Fiduciary best practice under ERISA requires plan sponsors to negotiate contract terms that capture all sources of revenue derived from plan volume.

Clinical Cost-Containment & Utilization Management Tools

To balance participant access to essential therapies with economic sustainability, plan sponsors and PBMs deploy targeted Utilization Management (UM) protocols:

Prior Authorization (PA) : Requires the prescribing physician to submit clinical documentation establishing that the patient meets specific evidence-based criteria before the PBM approves coverage. PA is commonly applied to high-cost medications, drugs with significant safety risks, or agents vulnerable to off-label overutilization.

Step Therapy ('Fail-First' Protocols) : Requires the patient to first try and fail a clinically proven, lower-cost first-line therapy (typically a generic medication) before the plan will approve coverage for a more expensive second-line or brand-name drug in the same therapeutic class.

Quantity Limits (QL) : Caps the number of dosage units dispensed within a defined timeframe (e.g., 30 tablets per 30 days or a maximum daily milligram dose). QLs align dispensing with FDA-approved dosing schedules, prevent waste, reduce stockpiling, and curb potential abuse (notably for opioids and controlled substances).

Mandatory Generic Substitution & 'Dispense as Written' (DAW) Penalties : When a multi-source brand drug has an FDA-approved generic equivalent (AB-rated), the plan covers only the generic cost. If a participant elects to receive the brand-name drug (DAW 2), the member pays the standard Tier 1 copay plus the full financial difference between the brand acquisition cost and the generic acquisition cost.

Mail-Order & 90-Day Retail Networks : For maintenance medications taken for chronic conditions (e.g., antihypertensives, statins), plans incentivize 90-day supplies through mail-order pharmacies or specialized retail networks ('Retail 90'). Plan sponsors benefit from deeper unit-cost discounts and lower aggregate dispensing fees, while members receive cost-sharing discounts (e.g., paying 2 monthly copays for a 3-month supply).

Specialty Pharmacy Management, Biologics & Emerging Solutions

Specialty pharmaceuticals —including recombinant proteins, monoclonal antibodies, cellular therapies, and gene therapies—represent less than 2%–3% of total prescription volume but account for more than 50% of total pharmacy expenditure in employer benefit plans. Specialty medications treat complex, chronic, or rare diseases such as rheumatoid arthritis, oncology, multiple sclerosis, and inflammatory bowel disease.

Biosimilars & Interchangeability

Unlike small-molecule generic drugs produced through chemical synthesis, biologics are complex, large-molecule proteins derived from living biological systems. Under the Biologics Price Competition and Innovation Act (BPCI Act) , the FDA approves biosimilars via the 351(k) pathway upon demonstrating that the drug is highly similar to the reference biologic with no clinically meaningful differences in safety, purity, or potency.

An interchangeable biosimilar meets additional statutory standards, allowing pharmacists to substitute the biosimilar for the reference product at the pharmacy counter without prescriber intervention, subject to state pharmacy laws. The rapid emergence of biosimilars for blockbuster biologics (e.g., adalimumab, infliximab, trastuzumab) creates substantial savings opportunities when PBMs align formulary tiering to promote biosimilar adoption.

Site-of-Care Optimization

Many specialty infused biologics are billed under the medical benefit rather than the pharmacy benefit. When administered in a hospital outpatient department (HOPD), facility fees and hospital markups often inflate the cost to 200%–400% of the drug's acquisition cost. Site-of-Care Optimization programs mandate or incentivize the transition of stable patients from HOPDs to lower-cost, clinically equivalent settings, including ambulatory infusion centers (AICs) , physician offices, or home infusion by specialized infusion nurses.

Copay Accumulator vs. Copay Maximizer Programs

To help patients manage high coinsurance on specialty drugs, pharmaceutical manufacturers offer commercial copay assistance cards (coupons) . While these coupons alleviate short-term patient financial burden, they can undermine formulary tiering and accelerate plan deductible exhaustion. Employers deploy two primary strategies:

Copay Accumulator Adjustment Programs : The PBM allows the manufacturer coupon to pay the member's initial out-of-pocket costs at the pharmacy counter, but the coupon value does not count toward the member's annual deductible or Out-of-Pocket Maximum (OOPM). Once the coupon maximum dollar limit is exhausted, the patient must pay their full deductible and coinsurance out of pocket.

Copay Maximizer Programs : The plan reclassifies specialty medications as 'non-essential health benefits' (under ACA definitions) where permissible, setting the patient cost-sharing rate to match the exact maximum annual value of the manufacturer coupon divided across twelve months. The coupon covers 100% of the patient liability with $0 out of pocket for the member, and zero coupon dollars accrue to the medical OOPM, maximizing plan savings without imposing sudden mid-year financial shock on the employee.

Loading diagram... Pharmacy Benefit Adjudication & Financial Cash Flows